专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240226035A1 Precision Medicine Approach to Treating Parkinson's Disease with a Monoamine Oxidase Inhibitor, an Antioxidant, or Both 审中-公开
公开(公告)号：US20240226035A1
公开(公告)日：2024-07-11
申请号：US18559087
申请日：2022-05-04
申请人： UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH
发明人： O'Bryant Sid E.
IPC分类号： A61K31/137 , A61K31/015 , A61K31/07 , A61K31/095 , A61K31/122 , A61K31/135 , A61K31/138 , A61K31/15 , A61K31/194 , A61K31/352 , A61K31/375 , A61K31/4045 , A61K31/42 , A61K31/421 , A61K31/4985 , A61K31/50 , A61K31/5375 , A61K33/00 , A61K33/04 , A61K38/06 , G16B25/10 , G16B40/20
CPC分类号： A61K31/137 , A61K31/015 , A61K31/07 , A61K31/095 , A61K31/122 , A61K31/135 , A61K31/138 , A61K31/15 , A61K31/194 , A61K31/352 , A61K31/375 , A61K31/4045 , A61K31/42 , A61K31/421 , A61K31/4985 , A61K31/50 , A61K31/5375 , A61K33/00 , A61K33/04 , A61K38/063 , G16B25/10 , G16B40/20
摘要： The present invention includes a method for selecting a subject for a targeted treatment for Parkinson's Disease, the method comprising: obtaining or having obtained a sample from the subject; measuring in the blood or serum sample the expression level of one or more first biomarkers; comparing the level of expression of the one or more first biomarkers from the subject's sample with the expression level of a corresponding one or more first biomarkers from a statistical sample representative of biomarkers in a normal subject; and if the subject is found to have a statistically different expression level of the one or more biomarkers when compared to the expression level of the corresponding one or more biomarkers from the statistical sample, treating the subject with a monoamine oxidase inhibitor, an antioxidant, or both.

2. 发明公开

US20240142473A1 PERSONALIZED MEDICINE APPROACH FOR TREATING COGNITIVE LOSS 审中-公开
公开(公告)号：US20240142473A1
公开(公告)日：2024-05-02
申请号：US18548840
申请日：2022-03-04
申请人： University of North Texas Health Science Center at Fort Worth
发明人： Sid E. O'BRYANT
IPC分类号： G01N33/68 , C12Q1/6876
CPC分类号： G01N33/6896 , C12Q1/6876 , C12Q2600/158 , G01N2800/52 , G01N2800/60
摘要： The present disclosure relates to a method of treating a subject having a proinflammatory endophenotype profile with celecoxib or naproxen to improve cognition or to prevent cognitive decline or dysfunction in the subject. In another aspect, the present disclosure relates to a method of screening a subject for inclusion an NSAID or a PPAR-7 agonist clinical trial. In another aspect, the present disclosure relates to a method of determining a surrogate outcome of an NSAID or a PPAR-7 agonist clinical trial. In yet another aspect, the present disclosure relates to a method of treating an Alzheimer's disease patient having both a proinflammatory endophenotype profile and a metabolic endophenotype profile with a PPAR-7 agonist to improve cognition or to prevent cognitive decline or dysfunction in the patient.

3. 发明授权

US11525834B2 Blood-based screen for detecting neurological diseases in primary care settings 有权
公开(公告)号：US11525834B2
公开(公告)日：2022-12-13
申请号：US14904244
申请日：2014-07-09
申请人： University of North Texas Health Science Center at Fort Worth , Board of Regents, The University of Texas System
发明人： Sid E. O'Bryant , Robert C. Barber , Guanghua Xiao , Dwight German
IPC分类号： G01N33/68 , G16B25/00 , G16B20/20 , G16B25/10 , A61B5/00 , G16B20/00 , G16B20/40
摘要： The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNFα biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.

4. 发明申请

US20220390474A1 Detection and Treatment of Conditions Related to Luteinizing Hormone/Follicle-Stimulating Hormone (LH/FSH) Levels 有权
公开(公告)号：US20220390474A1
公开(公告)日：2022-12-08
申请号：US17775040
申请日：2020-11-05
申请人： UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH
发明人： Dimitrios Karamichos
IPC分类号： G01N33/76
摘要： The present invention includes a method for detecting or predicting a disease or condition related to a ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH ratio) comprising: obtaining or having obtained a biological sample from a subject; and determining the LH/FSH ratio in the biological sample, wherein a decrease in the LH/FSH ratio when compared to an age-matched subject that does not have a disease or condition of LH/FSH is indicative of a current or future disease or condition of LH/FSH.

5. 发明授权

US09612245B2 Multiple-pulse pumping for enhanced fluorescence detection and molecular imaging in cells and tissue 有权
公开(公告)号：US09612245B2
公开(公告)日：2017-04-04
申请号：US14322998
申请日：2014-07-03
申请人： University of North Texas Health Science Center , Texas Christian University
发明人： Ryan M. Rich , Ignacy Gryczynski , Julian Borejdo , Zygmunt Gryczynski
IPC分类号： G01N21/64 , G01N33/58
CPC分类号： G01N33/582 , G01N21/6428 , G01N2201/0697
摘要： The present invention includes a method and system for enhancing the signal-to-noise ratio in emission detection comprising: selecting a probe capable of at least one of fluorescence, phosphorescence, or delayed fluorescence in or about a sample that comprises interfering background signal; and exposing the probe to one or more controllable bursts, each burst comprising two or more pulses, wherein the one or more controllable bursts of high repetition energy pulses enhance the signal from the probe above that of the background signal.

6. 发明授权

US08734853B2 HDL particles for delivery of nucleic acids 有权
标题翻译：用于递送核酸的HDL颗粒
公开(公告)号：US08734853B2
公开(公告)日：2014-05-27
申请号：US13129349
申请日：2009-11-17
申请人： Anil K. Sood , Andras G. Lacko , Gabriel Lopez-Berestein , Lingegowda S. Mangala , Walter J. McConathy , Laszlo Prokai , Maya P. Nair
发明人： Anil K. Sood , Andras G. Lacko , Gabriel Lopez-Berestein , Lingegowda S. Mangala , Walter J. McConathy , Laszlo Prokai , Maya P. Nair
IPC分类号： A61K9/14 , A61K31/7088 , A61K31/7105
CPC分类号： C07K14/775 , A61K47/6911 , A61K48/0041 , C12N15/111 , C12N15/88 , C12N2320/32
摘要： Disclosed are high density lipoprotein-nucleic acid particles, wherein the particles include (a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component. Also disclosed are pharmaceutical compositions that include a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region. Methods that concern the particles and pharmaceutical compositions of the present invention are also set forth, as well as kits.
摘要翻译：公开了高密度脂蛋白 - 核酸颗粒，其中颗粒包括（a）载脂蛋白; （b）包含治疗性核酸片段的核酸组分; 和（c）包含带正电荷区域的多肽，其中所述多肽的带正电区域与核酸组分结合。还公开了药物组合物，其包括a）载脂蛋白; （b）包含治疗性核酸片段的核酸组分; 和（c）包含带正电荷区域的多肽。还阐述了涉及本发明的颗粒和药物组合物的方法以及试剂盒。

7. 发明授权

US08159676B2 Ratiometric surface plasmon coupled emission detector 有权
标题翻译：比例表面等离子体耦合发射检测器
公开(公告)号：US08159676B2
公开(公告)日：2012-04-17
申请号：US12356288
申请日：2009-01-20
申请人： Zygmunt Gryczynski , Ignacy Gryczynski , Evgenia Matveeva , Julian Borejdo
发明人： Zygmunt Gryczynski , Ignacy Gryczynski , Evgenia Matveeva , Julian Borejdo
IPC分类号： G01N21/55
CPC分类号： G01N21/648 , G01N21/553
摘要： The present invention includes methods for ratiometric detection of analytes by surface plasmon coupled emission detection that includes disposing a target on the metal layer of a surface plasmon resonance detection system; coupling a first analyte to a first fluorescent dye and a second analyte to a second fluorescent dye; contacting the first and second analytes to the target on the surface plasmon resonance detection system; and measuring the intensity of a first and a second surface plasmon resonance enhanced fluorescence emission ring, wherein the first and second rings, respectively, quantitatively represents the amount of first and second analyte within 50 nanometers of the metal surface.
摘要翻译：本发明包括通过表面等离子体激元耦合发射检测对分析物进行比例检测的方法，其包括在表面等离子体共振检测系统的金属层上设置目标物; 将第一分析物与第一荧光染料和第二分析物耦合到第二荧光染料; 使第一和第二分析物与表面等离子体共振检测系统上的靶接触; 以及测量第一和第二表面等离子体共振增强荧光发射环的强度，其中第一和第二环分别定量地表示在金属表面的50纳米内的第一和第二分析物的量。

8. 发明申请

US20080193915A1 Isotope Labeled Dinitrophenylhydrazines and Methods of Use 审中-公开
标题翻译：同位素标记二硝基苯肼及其使用方法
公开(公告)号：US20080193915A1
公开(公告)日：2008-08-14
申请号：US11575253
申请日：2005-09-29
申请人： Laszlo Prokai , Michael J. Forster
发明人： Laszlo Prokai , Michael J. Forster
IPC分类号： C12Q1/70 , G01N33/00 , C12Q1/00 , G01N33/53 , C12Q1/02
CPC分类号： G01N33/60 , Y10T436/143333
摘要： The subject invention provides novel isotope-labeled dinitrophenylhydrazines (DNPHs) and methods for their use in detecting and/or quantifying carbonyl groups in proteins and other analytes. In particular, the present invention provides novel methods for identifying biomarkers of oxidative stress, which can be used to either forecast or detect diseases and/or conditions associated with oxidative stress. In one embodiment of the invention, isotope-labeled DNPHs are derived from [13C6]chlorobenzene.
摘要翻译：本发明提供新型同位素标记的二硝基苯肼（DNPH）及其用于检测和/或定量蛋白质和其它分析物中的羰基的方法。特别地，本发明提供用于鉴定氧化应激生物标志物的新方法，其可用于预测或检测与氧化应激相关的疾病和/或病症。在本发明的一个实施方案中，同位素标记的DNPH源自[13 C 6 C]氯苯。

9. 发明申请

US20080045419A1 Screening Assay 审中-公开
标题翻译：筛选测定
公开(公告)号：US20080045419A1
公开(公告)日：2008-02-21
申请号：US11840855
申请日：2007-08-17
申请人： Wolfram Siede
发明人： Wolfram Siede
IPC分类号： C40B30/04 , C40B60/12
CPC分类号： G01N33/6845 , C40B30/06 , G01N2500/10
摘要： The present invention includes a system and methods for the detection, isolation and characterization of candidate agents in a functional screening assay in agarose.
摘要翻译：本发明包括用于在琼脂糖的功能筛选测定中检测，分离和表征候选试剂的系统和方法。

10. 发明申请

US20040224995A1 Neuroprotective effects of PPARy agonists against cellular oxidative insults 审中-公开
标题翻译： PPARγ激动剂对细胞氧化损伤的神经保护作用
公开(公告)号：US20040224995A1
公开(公告)日：2004-11-11
申请号：US10435501
申请日：2003-05-09
申请人： University of North Texas Health Science Center at Fort Worth
发明人： James W. Simpkins , Paul Aoun
IPC分类号： A61K031/426
CPC分类号： A61K31/426
摘要： The current invention comprises compositions and methods for protecting a neuronal cell of a subject from a toxic insult. The method includes delivering an effective amount of a neuroprotective compound to the neuronal cells before or after the toxic insult. The neuroprotective compounds contain a peroxisome proliferator activated receptor (nullPPAR-nullnull) binding moiety with either a phenolic ring moiety or a prostaglandin (nullPGnull) with a reactive null,null-unsaturated carbonyl group on the cyclopentenone ring. Other novel compounds are also disclosed. The toxic insult that impinges upon the neuronal cell may be an acute process, or chronic disease process. Oxidative stress (e.g. hydrogen peroxide, and glutamate), injury, and secondary physiological responses to injury are among the acute processes discussed. Clinical disease processes that comprise oxidative stress, inflammatory responses, strokes, Alzheimer's disease, dementia, and Parkinson's disease are also addressed. Because PPAR-null agonists are used to treat type II diabetes, a condition that leads to neurological complications, a single agent that can target both conditions is of great therapeutic value.
摘要翻译：本发明包括用于保护受试者的神经元细胞免受有毒侮辱的组合物和方法。该方法包括在有毒侮辱之前或之后向神经元细胞递送有效量的神经保护性化合物。神经保护性化合物含有在环戊烯酮环上具有反应性α，β-不饱和羰基的酚环部分或前列腺素（“PG”）的过氧化物酶体增殖物激活受体（“PPAR-γ”）结合部分。还公开了其它新化合物。撞击神经元细胞的毒性侮辱可能是急性过程或慢性疾病过程。氧化应激（例如过氧化氢和谷氨酸盐），损伤和继发生的生理反应是讨论的急性过程。还讨论了包括氧化应激，炎症反应，中风，阿尔茨海默病，痴呆和帕金森病的临床疾病过程。因为PPAR-γ激动剂用于治疗II型糖尿病，导致神经系统并发症的病症，可以靶向两种病症的单一药物具有很大的治疗价值。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式